A Phase I Clinical Trial Evaluating Cellular Immunotherapy With Intratumoral Alloreactive Cytotoxic T Lymphocytes and Interleukin-2 for the Treatment of Recurrent Malignant Gliomas or Meningiomas

Jonsson Comprehensive Cancer Center1 site in 1 country10 target enrollmentJuly 2010

ConditionsGliomas Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Glioma Glioblastoma Multiforme Malignant Meningioma

Interventionsalloreactive CTL

Drugsalloreactive CTL

Overview

Phase: Phase 1
Intervention: alloreactive CTL
Conditions: Gliomas
Sponsor: Jonsson Comprehensive Cancer Center
Enrollment: 10
Locations: 1
Primary Endpoint: Number of patients with adverse events as a measure of safety and tolerability
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as aCTL cells, will be safe. This study will also try to determine if persons who receive aCTL's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. Approximately 15 patients will be enrolled at UCLA.

Registry

clinicaltrials.gov

Start Date

July 2010

End Date

July 2015

Last Updated

9 years ago

Study Type

Interventional

Study Design

Single Group